Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LM303 in advanced solid tumors
NCT06695689Phase 1Recruiting
- Sponsor
- Suzhou BlueHorse Therapeutics
- Start
- Oct 2024
- Primary completion
- Oct 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LM303 in solid tumor, melanoma, non-small cell lung cancer (NSCLC) and 1 more, sponsored by Suzhou BlueHorse Therapeutics. Primary endpoint: Incidence and severity of adverse events (AEs) at 1 year. Started Oct 2024; status: recruiting.
02
Drugs
LM303
03
Conditions
solid tumormelanomanon-small cell lung cancer (NSCLC)Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT06695689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06695689.